Clinical trials: Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery.
- Trial name
- NCT06186609
- Testing
- PD-1 inhibitor 200mg per three to four weeks, for one year
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Nantong University
Valid MeSH Conditions
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, multicenter, randomized, open-label, umbrella superiority clinical trial for patients with advanced metastatic esophageal squamous cell carcinoma who have not received prior anti-tumor treatment.
- Trial name
- NCT07709533
- Testing
- Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor
- Where
- China
- Volunteers
- 347 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
- Trial name
- NCT05182944
- Testing
- A：non-pCR patients, B：non-pCR patients, A：pCR patients
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE)
Neoadjuvant chemoradiotherapy treatment represents the standard approach for resectable locally advanced esophageal squamous cell carcinoma.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Surgery
- Trial name
- NCT04440332
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Cancer
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03736863
- Testing
- Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
- Where
- China
- Volunteers
- 147 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the malignant tumors with a high incidence worldwide, especially remaining persistently high in Asian regions.
- Trial name
- NCT07142421
- Testing
- Combination therapy (COMB)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
The purpose of this study is to explore the efficacy and safety of Toripalimab injection (JS001) given before and after concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04084158
- Testing
- Toripalimab injection (JS001), Paclitaxel, Albumin-Bound, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Optical Enhancement Endoscopy
Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell Carcinoma
the investigators randomly divide the eligible objects into two groups:1. objects in this group will first receive OE endoscopy observation and subsequent white light imaging(WLI) observation during oropharynx and hypopharynx; 2.
- Trial name
- NCT03700398
- Testing
- first OE, first WLI
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Shandong University
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT07266493
- Testing
- Chemotherapy （Albumin bound paclitaxel and Carboplatin）
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Esophageal Squamous Carcinoma
Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
- Trial name
- NCT03193424
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer, Chemoradiotherapy
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
This phase II clinical study is designed to evaluate the 1 year local tumor control rates after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy with nimotuzumab combined with S-1 in local…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm
- Trial name
- NCT04207918
- Testing
- Radiotherapy, Nimotuzumab, S-1
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Squamous Cell Carcinoma
Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer
This study examines contrast advantages and disadvantages of elective or prophylactic nodal irradiation in the treatment of esophageal cancer with three-dimensional conformed radiotherapy.
- Trial name
- NCT01551589
- Testing
- Involved Field Irradiation(IFI), docetaxel and cisplatin, Elective Nodal Irradiation (ENI)
- Where
- 4 sites in China
- Volunteers
- 220 people
- Sponsor
- Chengya Chou
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer.
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05911243
- Testing
- Acupressure Therapy, Best Practice, Biospecimen Collection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Esophageal Squamous Cell Carcinoma
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
This is a open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06690476
- Testing
- Dose escalation(IPM514 monotherapy), Dose expansion (IPM514 combined with tislelizumab), Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking University
Esophageal Cancer, Immunotherapy
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for…
- Conditions
- Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
- Trial name
- NCT06421376
- Testing
- Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.